stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) EBITDA
Trulieve Cannabis Corp.'s EBITDA for fiscal 2025 was $316.9M, up 20.0% from $264.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$104.9M. Over the past ten years it has ranged from −$51.0M (fiscal 2023) to $316.9M (fiscal 2025) — the current reading is the highest in ten years. Trulieve Cannabis Corp. ranks 74th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $316.9M | 19.97% |
| FY2024 | $264.2M | — |
| FY2023 | −$51.0M | — |
| FY2022 | $235.7M | (16.49%) |
| FY2021 | $282.3M | 13.59% |
| FY2020 | $248.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$327.4M | — |
| Mar 2026 | $79.2M | 33.33% |
| Dec 2025 | $59.4M | (29.25%) |
| Sep 2025 | $83.9M | (11.91%) |
| 18 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| ANIP ANI Pharmaceuticals, Inc. compare | $236.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $52.9M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| ALVO Alvotech compare | −$84.5M |
| TRLV Trulieve Cannabis Corp. | −$104.9M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$313.5M |
| PRGO Perrigo Company plc compare | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement